DOCSLIB.ORG

8Th Advances Against Aspergillosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
8Th Advances Against Aspergillosis 7th ADVANCES AGAINST ASPERGILLOSIS Manchester, United Kingdom 3 - 5 March 2016 Manchester Central Convention Complex www.AAA2016.org 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom Dear Advances Against Aspergillosis Colleague, This is now the 7th Advances Against Aspergillosis conference and the meeting continues to grow and change with the field. The previous six meetings were overwhelmingly successful, including the first meeting in 2004 (San Francisco) where we had 364 attendees from 28 countries, the second meeting in 2006 (Athens) with 464 attendees from 44 countries, the third meeting in 2008 (Miami) with 351 attendees from 48 countries, the fourth meeting in 2010 (Rome) with 533 attendees from 41 countries, the fifth meeting in 2012 (Istanbul) with 375 attendees from 39 countries, and the sixth meeting in 2014 (Madrid) with 342 attendees from 33 countries. Because of all of you, this conference has now established itself as the premier forum for discussion of all aspects of Aspergillus infection and research. The Aspergillus field continues in a state of rapid advancement, including the publication of numerous post- genomic papers and substantial advances in translational, immunologic, and diagnostic research. We have seen the launch of another effective antifungal for invasive aspergillosis (Isavuconazole) and anticipated clinical trials of newer compounds is an exciting time for mycology. Itraconazole, pan-azole, and echinocandin resistance has emerged, and combination therapy following the large trial remains an important area of interest. Greatly increased awareness of allergic aspergillosis has opened new market opportunities for both antifungal agents and immunotherapies. There is a continuing high death toll from invasive aspergillosis, particularly among patient groups not usually associated with this opportunistic infection. This meeting is another chance to gather the world’s aspergillosis experts in one venue. A fundamental tenet of this colloquium continues to be to engender collaborative relationships amongst clinicians, scientists, and industry to further advance the field. We thank the many corporate and foundation sponsors, listed in this program; without their support, this conference would not have been possible. We also thank the Scientific Committee for helping to assemble a truly international speaker list from the top centers in the world, with a focus on contemporary topics. By our design, much of the newest published literature and hypotheses in the field have originated from the speakers of this conference. In the program, we have introduced many speakers who did not speak at the previous Advances Against Aspergillosis meetings, including some young scientists and clinicians - a pattern we would like to repeat in future years. This year we have again increased the number of oral presentations from submitted abstracts to represent the wider community. We also thank all the speakers and poster presenters for contributing to the success of this effort. Please also join us at the welcome reception, the Basilea symposia, the tour and dinner, and the poster sessions. An essential part of this conference is the new friendships we expect will result, and the support of young scientists entering the field. The proceedings of this 7th meeting will once again be published in Medical Mycology, creating what we hope will be highlights of the newer insights from the many disciplines that encompass Aspergillus research and care. As Advances Against Aspergillosis has become the leading global meeting for basic and clinical science regarding Aspergillus, its efforts form one of the foundations of the repository of knowledge about this pathogen; 229 papers have been published in 7 Supplements, comprising 1,739 pages of full papers, as well as 1,061 abstracts from the meetings (not including this meeting). Our plan is to continue this conference every other year, and you will notice that there is a special open planning session for the next conference at the end of this meeting. We invite you to come and offer any suggestions for new sessions or topics or locations you would like to see in the future. Yours sincerely, William J. Steinbach David W. Denning David A. Stevens Co-Chairman Co-Chairman Co-Chairman 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom ACKNOWLEDGEMENTS We would like to offer very special thanks to the following organizations for their generous educational grants. Their financial support makes this conference possible. Gold Silver Bronze Others 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom TABLE OF CONTENTS Conference Chairmen, Scientific Committee ............................ 1 Faculty List ................................................................................... 3 Faculty Disclosures ...................................................................... 5 Poster Abstract Index .................................................................. 7 Scholarship Awards ..................................................................... 19 Final Programme Thursday 3 March .................................................................. 21 Friday 4 March ....................................................................... 24 Saturday 5 March .................................................................... 26 Abstracts Invited Faculty ........................................................................ 29 Difficult Cases of Invasive Mycoses ...................................... 67 Poster Abstracts ....................................................................... 73 Conference Sponsors ................................................................... 215 Author Index ................................................................................ 219 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom CONFERENCE CHAIRMEN AND SCIENTIFIC COMMITTEE Chairmen David W. Denning, FMedSci / University of Manchester, UK William J. Steinbach, MD / Duke University, USA David A. Stevens, MD / Stanford University, USA Scientific Committee Ritesh Agarwal, MD DM / Postgraduate Institute of Medical Education and Research, India Elaine Bignell, PhD / University of Manchester, UK Karl V. Clemons, PhD / Stanford University, USA Robert A. Cramer, Jr, PhD / Geisel School of Medicine at Dartmouth, USA Sean Doyle, PhD / National University of Ireland, Maynooth Jean-Paul Latgé, PhD / Institut Pasteur, France Richard B. Moss, MD / Stanford University, USA Thomas F. Patterson, MD / University of Texas - San Antonia, USA David S. Perlin, PhD / UMDNJ - New Jersey Medical School, USA Donald Sheppard, MD / McGill University, Canada Jörg-Janne Vehreschild, MD / University Hospital of Cologne, Germany - 1 - - 2 - 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom FACULTY Ritesh Agarwal, MD DM Sean Doyle, PhD Postgraduate Institute of Medical Education and National University of Ireland, Maynooth Research, India Rory A. Duncan, MS Ana Alastruey-Izquierdo, PhD National Institutes of Health (NIH), USA Instituto de Salud Carlos III, Spain Sybren de Hoog, PhD Darius Armstrong-James, FRCP MSc PhD Institute of the Royal Netherlands Academy of Arts DipMedMycol and Sciences (KNAW), The Netherlands Imperial College London, UK William Hope, FRACP PhD Elaine Bignell, PhD University of Liverpool, UK University of Manchester, UK Dimitrios P. Kontoyiannis, MD ScD FACP Axel A. Brakhage, PhD FIDSA Leibniz Institute for Natural Product Research, University of Texas MD Anderson Cancer Center, Germany USA Stéphane Bretagne, MD PhD Chris Kosmidis, MD PhD Institut Pasteur, France University Hospital of South Manchester, UK Michael Bromley, PhD Sven Krappmann, PhD University of Manchester, UK University Hospital Erlangen, Germany Karl V. Clemons, PhD Frederic Lamoth, MD Stanford University, USA Lausanne University Hospital, Switzerland Robert A. Cramer, PhD Jean-Paul Latgé, PhD Geisel School of Medicine at Dartmouth, USA Institut Pasteur, France Laurence Delhaes, MD PhD Stuart M. Levitz, MD University of Bordeaux, France University of Massachusetts Medical School, USA David W. Denning, FMedSci Michail S. Lionakis, MD ScD University of Manchester, UK National Institute of Allergy and Infectious Diseases, USA - 3 - 7th ADVANCES AGAINST ASPERGILLOSIS 3 - 5 March 2016 - Manchester, United Kingdom FACULTY Johan Maertens, MD PhD William J. Steinbach, MD University Hospitals Leuven, Belgium Duke University, USA Jacques F. Meis, MD PhD David A. Stevens, MD Canisius Wilhelmina Hospital, The Netherlands Stanford University, USA Richard B. Moss, MD Andrew J. Ullmann, MD Stanford University, USA Julius Maximilians University, Germany Eavan Muldoon, MBBCh MD MPH Jörg Janne Vehreschild, MD University Hospital of South Manchester, UK University Hospital of Cologne, Germany Mark R. Nicolls, MD Thomas J. Walsh, MD Stanford University, USA Weill Cornell Medical Center of Cornell University, USA Livio Pagano, MD Catholic University of Sacred Heart, Italy Li-Ping Zhu, PhD Fudan University, China Thomas F. Patterson, MD University of Texas – San Antonia, USA David S. Perlin, PhD UMDNJ – New Jersey Medical School, USA Malcolm Richardson, PhD University of Manchester, UK Seyedmojtaba Seyedmousavi, DVM PhD National Institutes of Health (NIH), USA Donald Sheppard, MD McGill University, Canada Anthony de Soyza, PhD MBChB Newcastle University, UK - 4 - 7th ADVANCES AGAINST ASPERGILLOSIS
Load more

Recommended publications
  • Superficial Fungal Infection
    Infeksi jamur superfisial (mikosis superfisialis) R. Wahyuningsih Dep. Parasitologi FK UKI 31 Maret 2020 Klasifikasi mikosis superfisialis berdasarkan penyebab • Dermatofitosis • kandidiasis superfisialis • Infeksi Malassezia/panu M. Raquel Vieira, ESCMID Dermatofitosis • Infeksi jaringan keratin (kulit, kuku & rambut) oleh jamur filamen gol. dermatofita • genus dermatofita – Tricophyton, – Microsporum – Epidermophyton, • ± 10 spesies menyebabkan dermatofitosis pada manusia Asian incidence of the most common mycoses identified All values are percentages In Asia, T. rubrum and T. mentagrophytes are the most commonly isolated pathogens, causing tinea pedis and unguium, as is the case in Europe. Havlickova et al, Mycoses Dermatophytosis di Indonesia • Geofilik: M . gypseum • Zoofilik: M. canis • Antropofilik: – T. rubrum – T. concentricum – E. floccosum Patologi & organ terinfeksi Kuku kulit rambut Trichophyton + + + Microsporum + + + Epidermophyton + + - http://www.njmoldinspection.com/mycoses/moldinfections.html Dermatophytoses...... • Gejala klinik tergantung pada: • Lokalisasi infeksi • Respons imun pejamu • Spesies jamur • Lesi: karakteristik (ring worm) tetapi dalam kondisi imuno supresi menjadi tidak khas perlu pemeriksaan laboratorium Dermatofita & dermatofitosis T. rubrum: biakan. kapang, pigmen merah, mikrokonidia lonjong, tetesan air mata/anggur, makrokonidia seperti pinsil/cerutu . antropofilik, . kelainan kronik mis. • tinea kruris, onikomiksosis De Berker, N Engl J Med 2009;360:2108-16 Dermatofita & dermatofitosis M. canis
    [Show full text]
  • Fusarium Subglutinans a New Eumycetoma Agent
    Medical Mycology Case Reports 2 (2013) 128–131 Contents lists available at SciVerse ScienceDirect Medical Mycology Case Reports journal homepage: www.elsevier.com/locate/mmcr Fusarium subglutinans: A new eumycetoma agent$ Pablo Campos-Macías a, Roberto Arenas-Guzmán b, Francisca Hernández-Hernández c,n a Laboratorio de Microbiología, Facultad de Medicina, Universidad de Guanajuato, León, Guanajuato 37320, México b Sección de Micología, Hospital General Dr. Manuel Gea González, México D.F. 14080, México c Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, México D.F. 04510, México article info abstract Article history: Eumycetoma is a chronic subcutaneous mycosis mainly caused by Madurella spp. Fusarium opportunistic Received 31 May 2013 infections in humans are often caused by Fusarium solani and Fusarium oxysporum. We report a case of Received in revised form eumycetoma by F. subglutinans, diagnosed by clinical aspect and culture, and confirmed by PCR 20 June 2013 sequencing. The patient was successfully treated with oral itraconazole. To our knowledge, this is the Accepted 26 June 2013 second report of human infection and the first case of mycetoma by Fusarium subglutinans. & 2013 The Authors. Published by Elsevier B.V on behalf of International Society for Human and Animal Keywords: Mycology All rights reserved. Eumycetoma Mycetoma Fusarium subglutinans Itraconazole 1. Introduction eye infections [7,8], and infections of immunosuppressed patients [9]. To our knowledge, there had been only 1 case of Fusarium Mycetoma is an infectious, inflammatory and chronic disease subglutinans infection documented in the literature, a hyalohypho- that affects the skin and subcutaneous tissue. Regardless of the mycosis case in a 72-year-old seemingly immunocompetent patient aetiologic agent (bacteria or fungi), the clinical disease is essen- [10].
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St
    Burden of serious fungal infections in Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St. James School of Medicine, Kralendjik, Bonaire (Dutch Caribbean). 1 LEADING WI The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. INTERNATIONAL 2 FUNGAL The University Hospital of South Manchester, (*Corresponding Author) National Aspergillosis Centre (NAC) Manchester, U.K. EDUCATION Background and Rationale The incidence and prevalence of fungal infections in Jamaica is unknown. The first human case of Conidiobolus coronatus infection was discovered in Jamaica (Bras et al. 1965). Cases of histoplasmosis and eumycetoma are reported (Fincharn & DeCeulaer 1980, Nicholson et al., 2004; Fletcher et al, 2001). Tinea capitis is very frequent in children Chronic pulmonary (East-Innis et al., 2006), because of the population being aspergillosis with aspergilloma (in the left upper lobe) in a 53- predominantly of African ancestry. In a one year study of 665 HIV yr-old, HIV-negative Jamaican male, developing after one infected patients, 46% of whom had CD4 cell counts <200/uL, 23 had year of antitubercular treatment; his baseline IgG pneumocystis pneumonia and 3 had cryptococcal meningitis (Barrow titer was 741 mg/L (0-40). As a smoker, he also had moderate et al. 2010). We estimated the burden of fungal infections in Jamaica emphysema. from published literature and modelling. Table 1. Estimated burden of fungal disease in Jamaica Fungal None HIV Respiratory Cancer ICU Total Rate Methods condition /AIDS /Tx burden 100k We also extracted data from published papers on epidemiology and Oesophageal ? 2,100 - ? - 2,100 77 from the WHO STOP TB program and UNAIDS.
    [Show full text]
  • Fungal Infections
    FUNGAL INFECTIONS SUPERFICIAL MYCOSES DEEP MYCOSES MIXED MYCOSES • Subcutaneous mycoses : important infections • Mycologists and clinicians • Common tropical subcutaneous mycoses • Signs, symptoms, diagnostic methods, therapy • Identify the causative agent • Adequate treatment Clinical classification of Mycoses CUTANEOUS SUBCUTANEOUS OPPORTUNISTIC SYSTEMIC Superficial Chromoblastomycosis Aspergillosis Aspergillosis mycoses Sporotrichosis Candidosis Blastomycosis Tinea Mycetoma Cryptococcosis Candidosis Piedra (eumycotic) Geotrichosis Coccidioidomycosis Candidosis Phaeohyphomycosis Dermatophytosis Zygomycosis Histoplasmosis Fusariosis Cryptococcosis Trichosporonosis Geotrichosis Paracoccidioidomyc osis Zygomycosis Fusariosis Trichosporonosis Sporotrichosis • Deep / subcutaneous mycosis • Sporothrix schenckii • Saprophytic , I.P. : 8-30 days • Geographical distribution Clinical varieties (Sporotrichosis) Cutaneous • Lymphangitic or Pulmonary lymphocutaneous Renal Systemic • Fixed or endemic Bone • Mycetoma like Joint • Cellulitic Meninges Lymphangitic form (Sporotrichosis) • Commonest • Exposed sites • Dermal nodule pustule ulcer sporotrichotic chancre) (Sporotrichosis) (Sporotrichosis) • Draining lymphatic inflamed & swollen • Multiple nodules along lymphatics • New nodules - every few (Sporotrichosis) days • Thin purulent discharge • Chronic - regional lymph nodes swollen - break down • Primary lesion may heal spontaneously • General health - may not be affected (Sporotrichosis) (Sporotrichosis) Fixed/Endemic variety (Sporotrichosis) •
    [Show full text]
  • Mycetoma: New Hope for Neglected Patients?
    MYCETOMA: NEW HOPE FOR NEGLECTED PATIENTS? Developing effective treatments for a truly neglected disease DNDi MYCETOMA: NEW HOPE FOR NEGLECTED PATIENTS? Among the most neglected of neglected tropical diseases, the fungal form of mycetoma, eumycetoma, has no effective treatment. Currently, eumycetoma is managed with sub-optimal drugs and surgery, including amputation of affected limbs. An effective, affordable, and easy-to-administer treatment is urgently needed. Mycetoma is a slow-growing Photo: Abraham Ali/Imageworks/DNDi. bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care. Due to the lack of effectiveness of available treatment, most lesions do not heal and instead recur on other parts of the body, leading to amputation and sometimes repeated amputations. In rare cases, when it affects the lungs or the brain, it can be fatal. In all instances patients are unable to work and often face severe social stigma. Mycetoma is so neglected that until 2016, it was not even listed in the World Health Organization’s list of neglected tropical diseases. Despite the impact of mycetoma, there has been little or no I got mycetoma 19 years ago after I was pricked funding or research attention to the disease until very recently. by a thorn. Even after numerous treatments, eight surgeries, and finally an amputation of my Mycetoma is so neglected that leg, I don’t think I am healed. I dropped out of until 2016, it was not even listed in the World Health Organization’s school after my first surgery and I had to stop list of neglected tropical diseases.
    [Show full text]
  • Actinomycetoma: an Update on Diagnosis and Treatment
    Actinomycetoma: An Update on Diagnosis and Treatment Roberto Arenas, MD; Ramón Felipe Fernandez Martinez, MD; Edoardo Torres-Guerrero, MD; Carlos Garcia, MD PRACTICE POINTS • Diagnosis of actinomycetoma is based on clinical manifestations including increased swelling and deformity of affected areas, presence of granulation tissue, scars, abscesses, sinus tracts, and a purulent exudate containing microorganisms. • The feet are the most commonly affected location, followed by the trunk (back and chest), arms, forearms, legs, knees, and thighs. • Specific diagnosis of actinomycetoma requires clinical examination ascopy well as direct examination of culture and biopsy results. • Overall, the cure rate for actinomycetoma ranges from 60% to 90%. not Mycetoma is a chronic infection that develops ycetoma is a subcutaneous disease that can after traumatic inoculation of the skin with eitherDo be caused by aerobic bacteria (actinomy- true fungi or aerobic actinomycetes. The resultant Mcetoma) or fungi (eumycetoma). Diagnosis infections are known as eumycetoma or actinomy- is based on clinical manifestations, including swell- cetoma, respectively. Although actinomycetoma is ing and deformity of affected areas, as well as rare in developed countries, migration of patients the presence of granulation tissue, scars, abscesses, from endemic areas makes knowledge of this con- sinus tracts, and a purulent exudate that contains dition crucial for dermatologists worldwide. We the microorganisms. present a review of the current concepts in the The worldwide proportion of mycetomas is epidemiology, clinical presentation,CUTIS diagnosis, 60% actinomycetomas and 40% eumycetomas.1 The and treatment of actinomycetoma. disease is endemic in tropical, subtropical, and tem- Cutis. 2017;99:E11-E15. perate regions, predominating between latitudes 30°N and 15°S.
    [Show full text]
  • Mycetoma: a Clinical Dilemma in Resource Limited Settings Pembi Emmanuel1,2,3, Shyam Prakash Dumre1, Stephen John4, Juntra Karbwang5* and Kenji Hirayama1
    Emmanuel et al. Ann Clin Microbiol Antimicrob (2018) 17:35 Annals of Clinical Microbiology https://doi.org/10.1186/s12941-018-0287-4 and Antimicrobials REVIEW Open Access Mycetoma: a clinical dilemma in resource limited settings Pembi Emmanuel1,2,3, Shyam Prakash Dumre1, Stephen John4, Juntra Karbwang5* and Kenji Hirayama1 Abstract Background: Mycetoma is a chronic mutilating disease of the skin and the underlying tissues caused by fungi or bacteria. Although recently included in the list of neglected tropical diseases by the World Health Organization, strategic control and preventive measures are yet to be outlined. Thus, it continues to pose huge public health threat in many tropical and sub-tropical countries. If not detected and managed early, it results into gruesome deformity of the limbs. Its low report and lack of familiarity may predispose patients to misdiagnosis and delayed treatment initia- tion. More so in situation where diagnostic tools are limited or unavailable, little or no option is left but to clinically diagnose these patients. Therefore, an overview of clinical course of mycetoma, a suggested diagnostic algorithm and proposed use of materials that cover the exposed susceptible parts of the body during labour may assist in the prevention and improvement of its management. Furthermore, early reporting which should be encouraged through formal and informal education and sensitization is strongly suggested. Main text: An overview of the clinical presentation of mycetoma in the early and late phases, clues to distinguish eumycetoma from actinomycetoma in the feld and the laboratory, diferential diagnosis and a suggested diagnostic algorithm that may be useful in making diagnosis amidst the diferential diagnosis of mycetoma is given.
    [Show full text]
  • Invasive Aspergillosis by Aspergillus Flavus
    Journal of Fungi Review Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management Shivaprakash M. Rudramurthy 1,2,* , Raees A. Paul 1 , Arunaloke Chakrabarti 1 , Johan W. Mouton 2 and Jacques F. Meis 3,4 1 Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Research, Chandigarh 160012, India 2 Department of Medical Microbiology and Infectious Diseases, Erasmus MC, 3015GD Rotterdam, The Netherlands 3 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital (CWZ) and Center of Expertise, 6532SZ Nijmegen, The Netherlands 4 Center of Expertise in Mycology Radboudumc/CWZ, 6532SZ Nijmegen, The Netherlands * Correspondence: [email protected]; Tel.: +91-1722755162 Received: 31 May 2019; Accepted: 29 June 2019; Published: 1 July 2019 Abstract: Aspergillus flavus is the second most common etiological agent of invasive aspergillosis (IA) after A. fumigatus. However, most literature describes IA in relation to A. fumigatus or together with other Aspergillus species. Certain differences exist in IA caused by A. flavus and A. fumigatus and studies on A. flavus infections are increasing. Hence, we performed a comprehensive updated review on IA due to A. flavus. A. flavus is the cause of a broad spectrum of human diseases predominantly in Asia, the Middle East, and Africa possibly due to its ability to survive better in hot and arid climatic conditions compared to other Aspergillus spp. Worldwide, ~10% of cases of bronchopulmonary aspergillosis are caused by A. flavus. Outbreaks have usually been associated with construction activities as invasive pulmonary aspergillosis in immunocompromised patients and cutaneous, subcutaneous, and mucosal forms in immunocompetent individuals. Multilocus microsatellite typing is well standardized to differentiate A.
    [Show full text]
  • Eumycetoma Caused by Cladophialophora Bantiana in a Dog J
    JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2004, p. 4901–4903 Vol. 42, No. 10 0095-1137/04/$08.00ϩ0 DOI: 10.1128/JCM.42.10.4901–4903.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Eumycetoma Caused by Cladophialophora bantiana in a Dog J. Guillot,1* D. Garcia-Hermoso,2 F. Degorce,3 M. Deville,1 C. Calvie´,4 G. Dickele´,5 F. Delisle,6 and R. Chermette1 Service de Parasitologie-Mycologie, UMR BIPAR,1 and Centre de Radiothe´rapie et Scanner,6 Ecole Nationale Ve´te´rinaire d’Alfort, Maisons-Alfort, Centre National de Re´fe´rence Mycologie et Antifongiques, Institut Pasteur, Paris,2 Laboratoire d’Anatomie Pathologique Ve´te´rinaire du Sud-Ouest, Toulouse,3 and Clinique Ve´te´rinaire de la Vieille Poste,4 and Clinique Ve´te´rinaire de Celleneuve,5 Montpellier, France Received 19 April 2004/Accepted 29 May 2004 We report a case of eumycetoma due to Cladophialophora bantiana in a 3-year-old male Siberian Husky living in France. The dog presented a tumefaction on the thorax and deformity of the second and third subjacent ribs, which were surgically removed. Macroscopic black granules were visible on the ribs, and direct microscopic Downloaded from examination revealed their fungal origin. Cultures yielded pure colonies of C. bantiana. The identification of the causative agent was confirmed after amplification and sequence analysis of fungal internal transcribed spacers 1 and 2 and 5.8S ribosomal DNA regions. Surgery and antifungal treatment with oral itraconazole associated with flucytosine allowed apparent cure after a 10-month follow-up. Envenomation with pine processionary caterpillars (Thaumetopoea pityocampa) and subsequently intensive corticotherapy were considered as possible predisposing factors.
    [Show full text]
  • Chaetomium Atrobrunneum Causing Human Eumycetoma: the First Report
    SYMPOSIUM Chaetomium atrobrunneum causing human eumycetoma: The first report Najwa A. Mhmoud1,2, Antonella Santona3, Maura Fiamma3, Emmanuel Edwar Siddig1, 3 1,4 3 Massimo Deligios , Sahar Mubarak BakhietID , Salvatore Rubino , Ahmed 1 Hassan FahalID * 1 Mycetoma Research Centre, University of Khartoum, Khartoum, Sudan, 2 Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan, 3 Department of Biomedical Sciences, University of Sassari, Sassari, Italy, 4 Institute for Endemic Diseases, University of Khartoum, Khartoum, Sudan * [email protected], [email protected] Author summary In this communication, a case of black grain eumycetoma produced by the fungus C. atro- a1111111111 brunneum is reported. The patient was initially misdiagnosed with M. mycetomatis eumy- a1111111111 cetoma based on the grains' morphological and cytological features. However, further a1111111111 aerobic culture of the black grains generated a melanised fungus identified as C. atrobrun- a1111111111 neum by conventional morphological methods and by internal transcribed spacer 2 a1111111111 (ITS2) ribosomal RNA gene sequencing. This is the first-ever report of C. atrobrunneum as a eumycetoma-causative organism of black grain eumycetoma. It is essential that the causative organism is identified to the species level, as this is important for proper patient management and to predict treatment outcome and prognosis. OPEN ACCESS Citation: Mhmoud NA, Santona A, Fiamma M, Siddig EE, Deligios M, Bakhiet SM, et al. (2019) Chaetomium atrobrunneum causing human Overview eumycetoma: The first report. PLoS Negl Trop Dis Mycetoma is a chronic, progressive, granulomatous, subcutaneous inflammatory disease. It is 13(5): e0007276. https://doi.org/10.1371/journal. pntd.0007276 caused by certain fungi and bacteria, and thus, it is classified as a eumycetoma and an actino- mycetoma, respectively.
    [Show full text]
  • Case Report: Onychomycosis Caused by Fusarium Dimerum
    Onychomycosis caused by Fusarium dimerum Reena Ray et al Case Report: Onychomycosis caused by Fusarium dimerum Reena Ray, 1 Mallika Ghosh,2 Mitali Chatterjee,1 Nibedita Chatterjee,1 Manas Banerjee,1 Department of 1Microbiology, R.G. Kar Medical College, Kolkata and Research officer, NICED, Kolkata ABSTRACT Fusraium is a non-dermatophytic hyaline mould found as soil saprophytes and plant pathogens. Human infections are probably a result of various precipitating predisposing factors of impaired immune status. Immunocompetent individuals of older age group are also vulnerable to various unassuming saprophytic and plant pathogen. We report 5 cases with onychomycosis caused by a rare species of Fusarium, namely, Fusarium dimerum. Fusarium is known to cause a variety of infections like keratitis, eumycetoma, onychomycosis, skin lesions and sometimes disseminated infection in individuals with impaired immunity. Hence it is of utmost importance to identify this newly emerging fungal pathogen correctly and institute appropriate treatment to control human infections at the earliest so that disseminated infections can be avoided. Key words: Fuserium dimerum, Onychomycosis, Immunocompetent individuals Ray R, Ghosh M, Chatterjee M, Chatterjee N, Banerjee M. Onychomycosis caused by Fusarium dimerum. J Clin Sci Res 2016;5:44-8. DOI: http://dx.doi.org/10.15380/2277-5706.JCSR.14.062. INTRODUCTION cancers, organ transplant recipients and in burn patients.5,6 Here we report 5 cases with Onychomycosis refers to fungal infection of the onychomycosis caused by a rare species of nail that results in thickening, discolouration, Fusarium, namely, Fusarium dimerum. disfiguring and splitting of finger and toe nails. It is frequently caused by dermatophytes: but CASE REPORTS now, non-dermatophytic moulds are known to Five patients presented to Dermatology out- account for 2%-12% of the nail infections.1 patients department (OPD) between June- Fungal infections may occur following trauma September months at our hospital in Kolkata, 2 or wound contamination.
    [Show full text]